Hostname: page-component-745bb68f8f-d8cs5 Total loading time: 0 Render date: 2025-01-12T02:56:35.088Z Has data issue: false hasContentIssue false
  • English
  • Français

Poliomyelitis: Eradication in sight

Published online by Cambridge University Press:  15 May 2009

Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Great strides have been made towards the control of poliomyelitis since the introduction of the two poliovaccines – inactivated poliovirus vaccine (IPV), which was licensed in the United States in 1954, and live attenuated oral poliovaccine (OPV), in 1961. Today a large majority of physicians and other health–care workers in industrialized countries never see a patient with paralytic poliomyelitis. Unfortunately, this is far from the situation in many developing countries, particularly in tropical and subtropical climates, where hundreds of thousands of children still become paralysed victims, year in and year out.

Type
Special Article
Information
Epidemiology & Infection , Volume 108 , Issue 1 , February 1992 , pp. 1 - 18
Copyright
Copyright © Cambridge University Press 1992

References

REFERENCES

1.Melnick, Jl. Enteroviruses. In: Evans, As, ed. Viral infections of humans: epidemiology and control. New York: Plenum, 3rd Ed., 1989: 191–263.CrossRefGoogle Scholar
2.Nkowane, BM, Wassilak, SGF, Orenstein, WA, Bart, KJ, Schonberger, LB, Hinman, AR. Vaccine–associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA 1987; 257: 1335–40.Google ScholarPubMed
3.Horstman, DM, Quinn, TC, Robbins, FC, eds. International Symposium on Poliomyelitis Control. Rev Inf Dis 1984; 6 (Suppl. 2): S301–600.Google Scholar
4.Centers for Disease Control. Update: Progress toward eradicating poliomyelitis from the Americas. MMWR 1990; 39: 557–61.Google Scholar
5.World Health Organization Expanded Programme on Immunization. Poliomyelitis in. 1987, 1988, 1989, Parts I and II. Weekly Epidem Rec 1991; 66: 49–53, 70–2.Google Scholar
6.Schaap, GJP, Bijkerk, H, Coutinho, RA, Kapsenberg, JG, van Wezel, AL. The spread of wild poliovirus in the well–vaccinated Netherlands in connection with the 1978 epidemic. Prog Med Virol 1984; 29: 124–49.Google ScholarPubMed
7.Hovi, T, Huovilainen, A, Kuronen, T et al. , Outbreak of paralytic poliomyelitis in Finland: Widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet 1986; I: 1427–35.CrossRefGoogle Scholar
8.Green, MS, Handsher, R, Cohen, D et al. , Age differences in immunity against wild and vaccine strains of poliovirus prior to the 1988 outbreak in Israel: Evidence supporting the need for a booster immunization in adolescents. Submitted for publication. 1991.Google Scholar
9.World Health Organization. Poliomyelitis in 1980, Parts 1 and 2. Weekly Epidem Rec 1981; 56: 329–36; 337–44.Google Scholar
10.World Health Organization. Poliomyelitis in 1985, Parts I and II. Weekly Epidem Rec 1987; 62: 273–80; 281–2.Google Scholar
11.World Health Organization. Poliomyelitis in 1979, Parts I and II. Weekly Epidem Rec 1980; 55: 361–6, 369–76.Google Scholar
12.Pan American Health Organization. Expanded Program on Immunization, Polio surveillance in the Americas. Weekly Bulletin vol. II, 50, for week ending 12 19, 1987.Google Scholar
13.Melnick, JL. Advantages and disadvantages of killed and live poliomyelitis vaccines. Bull WHO 1978; 56: 21–38.Google ScholarPubMed
14.Stoeckel, P, Schlumberger, M, Parent, G et al. , Use of killed poliovirus vaccine in a routine immunization program in West Africa. Rev Infect Dis 1984; 6 (Suppl. 2): S463–66.CrossRefGoogle Scholar
15.McBean, AM, Thoms, ML, Albrecht, P, Cuthie, JC, Bernier, R, and the Field Staff Coordinating Committee. The serologic response to oral polio vaccine and enhanced potency inactivated polio vaccines. Am J Epid 1988; 128: 615–28.CrossRefGoogle ScholarPubMed
16.Centers for Disease Control. Preliminary report: Paralytic poliomyelitis – Senegal, 1986. MMWR 1987; 36: 387–90.Google Scholar
17.WHO 1985.Google Scholar
18.Cockburn, WC. The work of the WHO Consultative Group on Poliomyelitis Vaccines. Bull WHO 1988; 66: 143–54.Google Scholar
19.Patriarca, PA, Palmeira, G, Filho, JL et al. , Randomised trial of alternative formulations of oral poliovaccine in Brazil. Lancet 1988; I: 429–33.CrossRefGoogle Scholar
20.Lasch, EE, Abed, Y, Abdulla, K et al. , Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza. Rev Infect Dis 1984; 6 (Suppl. 2): S467–70.CrossRefGoogle ScholarPubMed
21.Sabin, AB. Paralytic poliomyelitis: Old dogmas and new perspectives. Rev Infect Dis 1981; 3: 543–64.CrossRefGoogle ScholarPubMed
22.Sabin, AB. Oral poliovirus vaccine: History of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985; 151: 420–36.CrossRefGoogle ScholarPubMed
23.Robinson, DA. Polio vaccination – a review of strategies. Trans Roy Soc Trop Med & Hyg 1982; 76: 575–81.CrossRefGoogle ScholarPubMed
24.WHO 1985; 60: 13–16.Google Scholar
25.Foster, SO, Kesseng-Maben, G, N'jie, H., Coffi, E. Control of poliomyelitis in Africa. Rev Infect Dis 1984; 6 (Suppl. 2): S433–7.CrossRefGoogle ScholarPubMed
26.Henderson, RH, Sundaresan, T. Cluster sampling to assess immunization coverage: a review of experience with a simplified sampling methodology. Bull WHO 1982; 60: 253–60.Google Scholar
27.Ofosu-Amaah, S, Kratzer, JH, Nicholas, DD. Is poliomyelitis a serious problem in developing countries? Lameness in Ghanaian schools. BMJ 1977; I: 1012–14.CrossRefGoogle Scholar
28.Bernier, RH. Prevalence survey techniques for paralytic polio: An update. Expanded Programme on Immunization Working Paper, EPI/GAG 83/10. Geneva, World Health Organization, 1983.Google Scholar
29.Heymann, DL, Floyd, VD, Luchnevski, M, Kesseng-Maben, G, Mvongo, F. Estimation of incidence of poliomyelitis by three survey methods in different regions of the United Republic of Cameroon. Bull WHO 1983; 61: 501–7.Google ScholarPubMed
30.LaForce, FM, Lichnevski, MS, Keja, J, Henderson, RH. Clinical survey techniques to estimate prevalence and annual incidence of poliomyelitis in developing countries. Bull WHO 1980; 58: 609–20.Google ScholarPubMed
31.Heymann, DL, Murphy, K, Brigaud, M, Aymard, M, Tembon, A, Maben, GK. Oral poliovirus vaccine in tropical Africa. Bull WHO 1987; 65: 495–501.Google ScholarPubMed
32.Melnick, JL, Ashkenazi, A, Midulla, VC, Wallis, C, Bernstein, A. Immunogenic potency of MgCl2–stabilized oral poliovaccine. JAMA 1963; 185: 406–8.CrossRefGoogle Scholar
33.Peetermans, J, Colinet, G, Stephenne, J. Activity of attenuated poliomyelitis and measles vaccines exposed at different temperatures. In: Proceedings Symposium on Stability and Effectiveness of Measles, Poliomyelitis, and Pertussis Vaccines. Zagreb: Yugoslav Academy of Sciences and Arts, 1976: 61–6.Google Scholar
34.Finter, NB, Ferris, R, Kelly, A, Prydie, J. Effects of adverse storage on live virus vaccines. Dev Biol Stand 1978; 41: 61–6.Google ScholarPubMed
35.Mirchamsy, H, Shafyi, A, Mahinpour, M, Nazari, P. Stabilizing effect of magnesium chloride and sucrose on Sabin live polio vaccine. Dev Biol Stand 1978; 41: 255–7.Google ScholarPubMed
36.World Health Organization Poliomyelitis annual reports for 1974–1985. Weekly Epidem Rec, 1976–1987.Google Scholar
37.Risi, JB Jr. The control of poliomyelitis in Brazil. Rev Inf Dis 1984; 6 (Suppl. 2): S400–3.CrossRefGoogle Scholar
38.Fernandez de Castro, PJ. Comments on the geographic distribution of poliomyelitis in the Americas: Notes for a program on continental eradication of poliomyelitis. (Translation.) Revista Salud Publica de Mexico 1984; 26: (no. 3, 05–06).Google Scholar
39.de Quadros, C, Andrus, JL, Olive, J-M, da Silveira, M et al. , Eradication of poliomyelitis: progress in the Americas. Pediat Inf Dis J 1991; 19: 222–9.CrossRefGoogle Scholar
40.Dave, KH. Report of Enterovirus Research Centre, Bombay, for 1986, published 1987.Google Scholar
41.John, TJ. Poliomyelitis in India: Prospects and problems of control. Rev Infect Dis 1984; 6 (Suppl. 2): S438–41.CrossRefGoogle ScholarPubMed
42.WHO Expanded Programme on Immunization. Contract system tested. Weekly Epidem Rec 1987; 62: 142–3.Google Scholar
43.Melnick, JL. Combined use of live and killed vaccines to control poliomyelitis in tropical areas. Dev Biol Stand 1981; 47: 265–73.Google ScholarPubMed
44.Goldblum, N, Swartz, T, Gerichter, CB, Handsher, R, Lasch, EE, Melnick, JL. The natural history of poliomyelitis in Israel,1949–1982. Prog Med Virol 1984; Vol 29: 115–23.Google ScholarPubMed
45.Slater, PE, Orenstein, WA, Morag, A et al. , Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet 1990; 335: 1192–8.CrossRefGoogle ScholarPubMed
46.Lasch, EE. Abed, Y, Marcus, O, Gerichter, CB, Melnick, JL. combined live and inactivated poliovirus vaccine to control poliomyelitis in a developing country – five years after. Dev Biol Stand 1986; 63: 137–43.Google Scholar
47.Tulchinsky, T, Abed, Y, Shaheen, S et al. , A ten–year experience in control of poliomyelitis through a combination of live and killed vaccines in two developing areas. Am J Public Hlth 1989; 79: 1648–52.CrossRefGoogle ScholarPubMed
48.von Magnus, H, Petersen, I. Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Rev Infect Dis 1984; 6 (Suppl. 2): S471–4.CrossRefGoogle ScholarPubMed
49.Ogra, PL, Faden, HS, Abraham, R, Duffy, LC, Sun, M, Minor, PD. Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Inf Dis 1991; 164: 191–4.CrossRefGoogle ScholarPubMed
50.Hogle, MJ, Chow, M, Filman, JD. Three-dimensional structure of poliovirus at 29 Å resolution. Science 1985; 229: 1358–65.CrossRefGoogle ScholarPubMed
51.Minor, PD, Ferguson, M, Evans, DMA, Almond, JW, Icenogle, JP. Antigenic structure of polioviruses of serotypes 1, 2, and 3. J Gen Virol 1986; 67: 1283–91.CrossRefGoogle Scholar
52.Wimmer, E, Emini, EA, Diamond, DC. Mapping neutralization domains of viruses. In: Notkins, AL, Oldstone, MBA, eds. Concepts in clinical pathogenesis, Vol 2. New York: Springer–Verlag, 1986: 159–73.CrossRefGoogle Scholar
53.Burke, KL, Almond, JW, Evans, DJ. Antigen chimeras of poliovirus. Prog Med Virol 1991; 38: 56–68.Google ScholarPubMed
54.Chumakov, KM, Powers, LB, Noonan, KE, Roninson, IB, Levenbook, IS. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci 1991; 88: 199–203.CrossRefGoogle ScholarPubMed
55.Ren, R, Costantini, F, Gorgacz, EJ, Lee, JJ, Racaniello, VR. Transgenic mice expressing a human poliovirus receptor: A new model for poliomyelitis. Cell 1990; 63: 353–62.CrossRefGoogle ScholarPubMed
56.Koike, S, Taya, C, Kurata, T et al. , Transgenic mice susceptible to poliovirus. Proe Natl Acad Sci 1991; 88: 951–5.CrossRefGoogle ScholarPubMed
57.Rotbart, HA. New methods of rapid enteroviral diagnosis. Prog Med Virol 1991; 38: 96–108.Google ScholarPubMed
58.da Silva, EE, Pallansch, MA, Holloway, BP, Oliveira, MJC, Schatzmayr, HG, Kew, OM. Oligonucleotide probes for the specific detection of the wild poliovirus types 1 and 3 endemic to Brazil. Intervirol 1991; 32: 149–59.CrossRefGoogle ScholarPubMed
59.Eggers, HJ. Notes on the pathogenesis of enterovirus infections. Med Microbiol Immunol 1990; 179: 297–306.CrossRefGoogle ScholarPubMed
60.Morrison, LA, Fields, BN. Parallel mechanisms in neuropathogenesis of enteric virus infections. J Virol 1991; 65: 2767–72.CrossRefGoogle ScholarPubMed